R. Carter Pate

R. Carter Pate
Director

Director of Teligent: 2021- Present

Mr. Pate is the founder and Chief Executive Officer of Carter Pate, LLC, a Family Private Equity Investment Company, and has served as a Board Member to public and private Boards of Directors since 2014. He is the former Chief Executive Officer of Providence Service Corp DBA LogistiCare (NASDAQ: PRSC), the largest non-emergency medical logistics company for Medicare and Medicaid. Mr. Pate currently serves on the Board, and is a member of the Audit Committee, of Optioncare Health (NASDAQ: OPCH) and was the Chairman of the Board of its predecessor, BioScrip Inc. (NASDAQ: BIOS).  He also serves as a member of the Board, the Chairman of its Compensation Committee, and a member of the Audit Committee, for Advanced Emissions Solutions (NASDAQ: ADES).  Mr. Pate served as a member of the Board of the Red Lion Hotels Group Corporation from May 2019 until March 2020.  Prior to these roles, Mr. Pate had a career with PricewaterhouseCoopers spanning nearly two decades, including his service as a Global/United States Managing Partner of U.S. Advisory and later the Health Care practice leader. In these roles he worked with Fortune 500 companies and G-20 governments with a focus on change management and cost realignment. For his first seven years at PwC, Mr. Pate led PwC’s restructuring practice. He is the author of best-selling financial restructuring book, “The Phoenix Effect: Nine Revitalizing Strategies No Business Can Do Without.”  Mr. Pate has certifications as a Certified Public Accountant and Certified Forensic Public Accountant and obtained his undergraduate degree in Accounting and a master’s degree in Accounting and Information Systems from University of Texas at Dallas.
 

William S. Marth

William S. Marth
Director

Director of Teligent: 2021- Present

Mr. Marth currently serves as the Managing Partner of North Ocean Ventures, LLC, a consulting firm that helps pharmaceutical businesses realize their full potential, and served as the Global President and Chief Executive Officer of North America & Europe of Avet Pharma Holdings Inc., a specialty generic pharmaceutical company and subsidiary of Emcure Pharmaceuticals Ltd from 2018 to 2020.  Previously, Mr. Marth served as the President and CEO of Albany Molecular Research, Inc. (AMRI), a global contract research and manufacturing company providing services to the pharmaceutical and biotechnology industries. Before that, Mr. Marth served in various senior leadership roles at Teva Pharmaceutical Industries Limited, including President and CEO of Teva Pharmaceuticals – Americas, as well as CEO of Teva North America and CEO of Teva USA, while also serving as a member of Teva’s global executive management team.  Mr. Marth has served and does serve on a number of Private and Charitable Boards.  Mr. Marth holds a Bachelor of Science in Pharmacy from the University of Illinois College of Pharmacy, a Master’s in Business Administration from the Keller Graduate School of Management, DeVry University, and an honorary Doctor of Humane Letters from the Albany College of Pharmacy and Health Sciences.